Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Coronary Intravascular Lithotripsy (IVL): Clinical Performance and Safety
Coronary intravascular lithotripsy (IVL) is an established plaque-modification technique designed to facilitate optimal stent expansion in moderately to severely calcified coronary lesions. By delivering localized acoustic pressure waves through a low-pressure balloon system, IVL induces controlled microfractures in both superficial and deep calcium, improving vessel compliance while minimizing vascular trauma.
Clinical evidence from the Disrupt CAD I–IV trials demonstrates a procedural success rate of approximately 92%, defined by successful stent delivery with residual stenosis below target thresholds and absence of in-hospital major adverse cardiac events. In these studies, residual stenosis <50% was achieved in approximately 95% of treated lesions, reflecting effective calcium modification and favorable acute luminal gain.
Importantly, IVL is associated with a low incidence of serious complications, including a coronary perforation rate below 1%, which is substantially lower than that reported with some atherectomy-based strategies. This safety profile, combined with technical simplicity and a short learning curve, supports IVL as a valuable option for contemporary percutaneous coronary intervention in calcified coronary artery disease.”
Title: Shocking the Rock With Coronary Intravascular Lithotripsy in Contemporary Practice
Authors: Debabrata Dash, Anna Emily Bortnic
Read the Full Article on American College of Cardiology
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study
-
Aug 21, 2026, 21:29Merlin Crossley: Atomic Precision in Sickle Cell Care – Structural Targeting for Fetal Globin Reactivation
-
Aug 21, 2026, 19:09Aphisit Thongthaisin: Admitted to Sorbonne University’s T2H University Diploma for 2026/2027
-
Aug 21, 2026, 19:07José Luis Ferreiro Gutiérrez: Proud to Be Elected Chairperson-Elect of the ESC Working Group on Thrombosis
-
Aug 21, 2026, 19:00Manuel Monreal: New RIETE Registry Data on VTE Recurrence and Bleeding During Anticoagulation
-
Aug 21, 2026, 18:39Ronak H. Mistry: Updated ASH ITP Guidelines Bring New Guidance for Managing ITP
-
Aug 21, 2026, 18:22Ahmed Bennis: NOAC Use Is Associated With Slower Cognitive Decline in AF and Alzheimer’s Disease